Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
RESEARCH TOOLSreports
Phathom Pharmaceuticals (PHAT) Stock Price & Analysis
247 Followers
PHAT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.07 - $17.02
Previous Close$10.95
Volume1.11M
Average Volume (3M)628.37K
Market Cap
$640.67M
Enterprise Value$398.30M
Total Cash (Recent Filing)$381.39M
Total Debt (Recent Filing)$139.03M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 08, 2024EPS Estimate
-$1.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.41
Shares Outstanding58,535,193
10 Day Avg. Volume535,550
30 Day Avg. Volume628,367
Standard Deviation0.20
R-Squared0.03
Alpha-0.00410
Financial Highlights & Ratios
Price to Book (P/B)-8.91
Price to Sales (P/S)950.98
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue584.02
Enterprise Value/Gross Profit773.41
Enterprise Value/Ebitda-2.53
Forecast
1Y Price Target
$26.00Price Target Upside137.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Phathom Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Market PotentialApproval in NERD is a positive and likely to accelerate the materializing of an inflection point in Voquezna sales growth.
Product InnovationVoquezna is recognized as the first innovation in the GERD space in decades, offering a novel benefit for patients who have tried PPIs.
Regulatory ApprovalFDA approval and label expansion for Voquezna cover approximately 65M annual adult GERD patients in the US, with roughly 22M diagnosed and treated with prescription therapy.
Bears Say
Commercialization TrendsAnalyst remains on the sidelines as they await normalization of commercialization trends.
Growth InflectionAnalyst awaits further evidence of sustainable, post-inflection growth.
Prescription DataV oquezna's weekly U.S. prescription data were flat.
---
Ownership Overview
40.23% Insiders
8.06% Mutual Funds
20.99% Other Institutional Investors
30.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $6.07 and its highest was $17.02 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Currently, no data Available
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$1.42 earnings per share for the quarter, missing the consensus estimate of -$1.321 by -$0.099.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -$1.32.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 58,535,194 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$1.42 in its last earnings report, missing expectations of -$1.321. Following the earnings report the stock price went down -0.099%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Among the largest hedge funds holding Phathom Pharmaceuticals’s share is Gilder Gagnon Howe & Co LLC.. It holds Phathom Pharmaceuticals’s shares valued at 11M.
---
Phathom Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (137.55% Upside)
$26.00 (137.55% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 948.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 12.5%
Last 30 Days ▲ 12.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
147.55%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
---
PHAT Earnings Call
Q1 2024
0:00 / 0:00
---
PHAT Stock 12 Month Forecast
Average Price Target
$26.00
▲(137.55% Upside)
Technical Analysis
Best Analysts Covering PHAT
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+9.43%
assigned a buy rating 7 months ago
Copying Sean Kim PhD's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +9.43% per trade.
---